Drugs & Aging

, Volume 19, Issue 5, pp 355–363 | Cite as

Treatment of Inflammatory Bowel Disease in the Elderly

An Update
  • Darrell S. Pardi
  • Edward V. LoftusJr
  • Michael Camilleri
Therapy In Practice

Abstract

Inflammatory bowel disease (IBD) is most common in young adults, but it can also present in the elderly. Furthermore, with the aging of the population, the number of elderly patients with IBD is expected to grow. Other conditions, such as diverticulitis and ischaemic colitis, may be more common in the elderly and need to be considered in the differential diagnosis. Management of elderly patients with IBD follows the same principles as in younger patients, with a few exceptions.

For patients with mild-to-moderate colitis, a 5-aminosalicylate drug is often used (sulfasalazine, olsalazine, mesalazine, balsalazide). Topical therapy may be sufficient for those with distal colitis, whereas an oral preparation is used for more extensive disease. In those with more severe or refractory symptoms, corticosteroids are used, although the elderly appear to be at increased risk for corticosteroid-associated complications. For patients with corticosteroid-dependent or corticosteroid-refractory disease, immunosuppression with azathioprine or mercaptopurine may help avoid surgery. In patients with Crohn’s disease, a similar approach is followed, with the additional consideration that the formulation of drug used must ensure delivery of drug to the site of inflammation. In fistulising Crohn’s disease, antibacterials, immunosuppressive drugs, infliximab and surgery are often used in combination. Controlled trials and clinical experience have shown that infliximab is a significant addition to the therapeutic armamentarium for patients with Crohn’s disease.

Keywords

Inflammatory Bowel Disease Ulcerative Colitis Infliximab Diverticulitis Mesalazine 

Notes

Acknowledgements

Dr. M. Camilleri is supported by grants RO1 DK54681-2 and K24 DK02638-2 from the US National Institutes of Health.

References

  1. 1.
    Robertson DJ, Grimm IS. Inflammatory bowel disease in the elderly. Gastroenterol Clin North Am 2001; 30: 409–26PubMedCrossRefGoogle Scholar
  2. 2.
    Russel M, Stockbrugger RW. Epidemiology of inflammatory bowel disease: an update. Scand J Gastroenterol 1996; 31: 417–27PubMedCrossRefGoogle Scholar
  3. 3.
    Farrell JJ, Friedman LS. Colitis in the elderly. In: TM Bayless, SB Hanauer, editors. Advanced therapy in inflammatory bowel disease. Hamilton: BC Decker, Inc., 2001: 619–24Google Scholar
  4. 4.
    Softley A, Myren J, Clamp SE, et al. Inflammatory bowel disease in the elderly patient. Scand J Gastroenterol Suppl. 1988; 144: 27–30PubMedGoogle Scholar
  5. 5.
    Regueiro MD, Peppercorn MA. Inflammatory bowel disease in the elderly. Resid Staff Physician 1995; 41: 41–6Google Scholar
  6. 6.
    Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut 2000; 46: 336–43PubMedCrossRefGoogle Scholar
  7. 7.
    Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Crohn’s disease in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gastroenterology 1998; 114: 1161–8PubMedCrossRefGoogle Scholar
  8. 8.
    Tedesco FJ, Hardin RD, Harper RN, et al. Infectious colitis endoscopically simulating inflammatory bowel disease: a prospective evaluation. Gastrointest Endosc 1983; 29: 195–7PubMedCrossRefGoogle Scholar
  9. 9.
    Wagtmans MJ, Verspaget HW, Lamers CB, et al. Crohn’s disease in the elderly: a comparison with young adults. J Clin Gastroenterol 1998; 27: 129–33PubMedCrossRefGoogle Scholar
  10. 10.
    Tchirkow G, Lavery IC, Fazio VW. Crohn’s disease in the elderly. Dis Colon Rectum 1983; 26: 177–81PubMedCrossRefGoogle Scholar
  11. 11.
    Peppercorn MA. Drug-responsive chronic segmental colitis associated with diverticula: a clinical syndrome in the elderly. Am J Gastroenterol 1992; 87: 609–12PubMedGoogle Scholar
  12. 12.
    Harper PC, McAuliffe TL, Beeken WL. Crohn’s disease in the elderly. A statistical comparison with younger patients matched for sex and duration of disease. Arch Intern Med 1986; 146: 753–5PubMedCrossRefGoogle Scholar
  13. 13.
    Norris B, Solomon MJ, Eyers AA, et al. Abdominal surgery in theolder Crohn’s population. Aust NZJ Surg 1999; 69: 199–204CrossRefGoogle Scholar
  14. 14.
    Polito JM, Childs B, Mellits ED, et al. Crohn’s disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996; 111: 580–6PubMedCrossRefGoogle Scholar
  15. 15.
    Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol 1997; 92: 204–11PubMedGoogle Scholar
  16. 16.
    Prakash A, Spencer CM. Balsalazide. Drugs 1998; 56: 83–9PubMedCrossRefGoogle Scholar
  17. 17.
    Thomas TPL. The complications of systemic corticosteroid treatment in the elderly. Gerontology 1984; 30: 60–5PubMedCrossRefGoogle Scholar
  18. 18.
    Akerkar GA, Peppercorn MA, Hamel MB, et al. Corticosteroidassociated complications in elderly Crohn’s disease patients. Am J Gastroenterol 1997; 92: 461–4PubMedGoogle Scholar
  19. 19.
    Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94: 878–83PubMedCrossRefGoogle Scholar
  20. 20.
    Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292–9PubMedCrossRefGoogle Scholar
  21. 21.
    Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91: 423–33PubMedGoogle Scholar
  22. 22.
    Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 1996; 30: 951–4PubMedGoogle Scholar
  23. 23.
    Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol 2001; 96: 635–43PubMedCrossRefGoogle Scholar
  24. 24.
    Targan S, Hanauer S, van Deventer S, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn’s disease. N Engl J Med 1997; 337: 1029–35PubMedCrossRefGoogle Scholar
  25. 25.
    Feagan BG. Methotrexate treatment for Crohn’s disease. Inflamm Bowel Dis 1998; 4: 120–1PubMedCrossRefGoogle Scholar
  26. 26.
    Landewe RB, van den Borne BE, Breedveld FC, et al. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 2000; 355: 1616–7PubMedCrossRefGoogle Scholar
  27. 27.
    Tett SE, Triggs EJ. Use of methotrexate in older patients. A risk-benefit assessment. Drugs Aging 1996; 9: 458–71PubMedCrossRefGoogle Scholar
  28. 28.
    Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn’s disease with intravenous cyclosporin. Am J Gastroenterol 1998; 93: 442–8PubMedCrossRefGoogle Scholar
  29. 29.
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340: 1398–405PubMedCrossRefGoogle Scholar
  30. 30.
    Lichtenstein GR. Treatment of fistulizing Crohn’s disease. Gastroenterology 2000; 119: 1132–47PubMedCrossRefGoogle Scholar
  31. 31.
    Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 761–9PubMedCrossRefGoogle Scholar
  32. 32.
    Camma C, Giunt M, Roselli M, et al. Mesalamine in the maintenance treatment of Crohn’s disease: meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113: 1465–73PubMedCrossRefGoogle Scholar
  33. 33.
    Korelitz B, Hanauer S, Rutgeerts P, et al. Post-operative prophylaxis with 6MP, 5-ASA or placebo in Crohn’s disease: a 2 year multicenter trial [abstract]. Gastroenterology 1998; 114: A1011CrossRefGoogle Scholar
  34. 34.
    Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis. Ann Intern Med 1997; 126: 364–71PubMedGoogle Scholar
  35. 35.
    Spencer CM, McTavish D. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995; 50: 854–72PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Darrell S. Pardi
    • 1
  • Edward V. LoftusJr
    • 1
  • Michael Camilleri
    • 1
  1. 1.Division of Gastroenterology and HepatologyMayo Clinic and FoundationRochesterUSA

Personalised recommendations